Navigation Links
New treatment offers hope for short-bowel syndrome patients
Date:7/18/2013

Bethesda, MD (July 18, 2013) A new drug, teduglutide, offers significant relief for patients with short-bowel syndrome intestinal failure who are reliant on intravenous nutrition, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. Patients with this relatively rare condition experience massive bowel loss and are unable to absorb nutrients, vitamins and water from digested foods. They rely on parenteral nutrition, or intravenous feeding, to deliver their daily nutrients.

"Short-bowel syndrome is a devastating condition, and without parenteral nutrition patients would not survive. However, this treatment method is labor-intensive, expensive and carries complications, including chronic infection, blood clots and liver failure," said Stephen J. D. O'Keefe, MD, MSc, FRCP, Division of Gastroenterology, University of Pittsburgh Medical School, PA, and lead study author. "Teduglutide, a new form of therapy, offers potential to significantly reduce intravenous nutrition dependency and improve the quality of life for patients."

Teduglutide is an injection administered once daily that helps improve intestinal absorption of fluids and nutrients, reducing the frequency and volume of parenteral nutrition.

Dr. O'Keefe and colleagues conducted a year-long trial to determine the safety, tolerability and clinical efficacy of teduglutide on patients with short-bowel syndrome. After 52 weeks, 68 percent of patients on just a low dose of teduglutide experienced lessened parenteral nutrition dependency and there was a greater than 20 percent reduction in IV-fluid requirements.

Remarkably, the study documented multiple patients who received complete independence from parenteral nutrition. These findings instill hope that short-bowel syndrome patients can achieve a significantly enhanced quality of life, free of sleep disturbances and limited social activities.

Teduglutide recently received FDA approval for individuals with short-bowel syndrome who are dependent on parenteral nutrition or intravenous therapy despite optimal medical management. There are no contraindications and no time limit on therapy. Physicians planning to prescribe the drug need to be knowledgeable in its use and potential side effects, which include gastrointestinal symptoms (abdominal pain, nausea, vomiting), headache and common cold-like symptoms. Further studies are needed to assess teduglutide's safety and efficacy long term.


'/>"/>

Contact: Rachel Steigerwald
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related biology news :

1. Molecular discovery puts cancer treatment in a new perspective
2. Which Prostate Cancers Really Need Treatment?
3. Lifesaving HIV treatment could reach millions more people following landmark study
4. Continued research needed on treatment for women with lung cancer who are never smokers
5. Artificial sweetener a potential treatment for Parkinsons disease
6. Posttraumatic stress disorder treatment: Genetic predictor of response to exposure therapy
7. Scientists identify potential drug target for treatment-resistant anemias
8. Neurochemical traffic signals may open new avenues for the treatment of schizophrenia
9. Addition of bevacizumab to initial treatment for brain tumors does not extend patients lives
10. Engineered stem cell advance points toward treatment for ALS
11. Using big data to identify prostate cancers and best treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):
(Date:5/27/2016)... ... , ... Doctors in Italy, Japan, the UK and the US have reached ... gene and its link to malignant mesothelioma. Surviving Mesothelioma has just posted the details ... now. , The studies analyzed for the new report included more than 3,447 ...
(Date:5/27/2016)... At present, the Biotech sphere is in a ... volatility is what makes this industry interesting to consider. Here ... (NASDAQ: SNTA ), CTI BioPharma Corp. (NASDAQ: ... and Heat Biologics Inc. (NASDAQ: HTBX ). Sign ... these stocks at: http://www.activewallst.com/register/ ...
(Date:5/26/2016)... and READING, England , May ... http://www.indegene.com ), a leading global provider of clinical, ... and healthcare organisations and TranScrip ( http://www.transcrip-partners.com ), ... throughout the product lifecycle, today announced the extension ... IntraScience.      (Logo: http://photos.prnewswire.com/prnh/20141208/720248 ...
(Date:5/26/2016)... -- Despite the volatility that continues to envelop ... pre-market research on ActiveWallSt.com directs the investor community,s focus on ... RDUS ), Cerus Corp. (NASDAQ: CERS ), Arrowhead ... Therapeutics Inc. (NASDAQ: FPRX ). Register with us ... http://www.activewallst.com/ On Wednesday, shares in ...
Breaking Biology Technology: